Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Atria Investments Inc

Atria Investments Inc lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 60.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,429 shares of the medical equipment provider’s stock after acquiring an additional 2,041 shares during the period. Atria Investments Inc’s holdings in Zimmer Biomet were worth $586,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Rovin Capital UT ADV raised its position in shares of Zimmer Biomet by 19.1% during the 3rd quarter. Rovin Capital UT ADV now owns 6,426 shares of the medical equipment provider’s stock valued at $694,000 after acquiring an additional 1,029 shares in the last quarter. Philip James Wealth Mangement LLC bought a new position in Zimmer Biomet during the 3rd quarter worth $305,000. Sittner & Nelson LLC grew its stake in Zimmer Biomet by 62.4% during the 3rd quarter. Sittner & Nelson LLC now owns 2,085 shares of the medical equipment provider’s stock worth $225,000 after buying an additional 801 shares during the last quarter. Olstein Capital Management L.P. grew its stake in Zimmer Biomet by 3.4% during the 3rd quarter. Olstein Capital Management L.P. now owns 80,000 shares of the medical equipment provider’s stock worth $8,636,000 after buying an additional 2,600 shares during the last quarter. Finally, Graypoint LLC grew its stake in Zimmer Biomet by 6.6% during the 3rd quarter. Graypoint LLC now owns 4,829 shares of the medical equipment provider’s stock worth $521,000 after buying an additional 299 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $110.95 on Wednesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $101.47 and a fifty-two week high of $133.90. The stock’s 50-day moving average is $106.56 and its two-hundred day moving average is $109.86. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a market cap of $22.09 billion, a P/E ratio of 21.09, a PEG ratio of 2.07 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period last year, the business earned $1.65 EPS. The business’s quarterly revenue was up 4.1% on a year-over-year basis. Analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZBH shares. BTIG Research lowered their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Oppenheimer decreased their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. JPMorgan Chase & Co. decreased their price target on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a research note on Monday, September 16th. Finally, Raymond James decreased their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.